glp 1 agonist or antagonist glp-1_analogs [TUSOM Glucagon-like peptide-1 - Wikipedia
Description
42 This benefit was primarily driven by a significant reduction in the incidence of new-onset persistent macroalbuminuria (HR 0.74
4 For example, ADA and KDIGO joint group has recommended that for patients with T2DM and CKD who do not achieve their glycemic target with metformin and/or an SGLT2i or cannot use them, a GLP-1RAs with proven cardiovascular benefit is recommended
Biliary complications (cholelithiasis, cholecystitis) represent a class effect attributable to reduced gallbladder motility, with incidence approximately 1.5-2.5-fold higher than placebo in long-term trials
Case Rep Gastroenterol
Such interest could result in GLP-1 penetration reaching nearly 20% of the US adult population within two years, and the pill format could expand the active GLP-1 user population by as much as 50% by 2027, according to Big Chalk
Even a modest 610% weight reduction can significantly improve IIH outcomes [5]
